Research and analysis

Confirmed cases of pertussis in England by month

Updated 14 May 2024

Applies to England

Confirmed cases of pertussis in England by month, to end March 2024

In England, there were 858 (provisional) new laboratory confirmed cases of pertussis reported to the UK Health Security (UKHSA) pertussis enhanced surveillance programme in 2023. Provisionally, 556 cases were laboratory-confirmed in January, 918 cases in February and 1,319 cases in March 2024. There have been 5 reported deaths in infants who developed pertussis in the first quarter of 2024 (January to March) ^{[footnote 1]}.

Intervention measures implemented to help control the spread of COVID-19 between March 2020 and July 2021 also had an impact on other infectious diseases, including pertussis. Consequently, pertussis activity was exceptionally low across England from April 2020 and persisted at low levels until Summer 2023 when case numbers began to increase (Figure 1). Overall numbers in 2023 remained lower than pre-pandemic years (Figure 2, Table 1). The recent increase in pertussis cases has been observed across all age groups and in every region in England and case numbers have continued to rise across the first 3 months of 2024, as expected based on usual seasonal patterns.

Of the 2,793 cases confirmed between January and March 2024, around half (1,420 cases, 50.8%) were in those aged 15 years or older and 28.6% were in children aged between 10 and 14 years (799 cases) (Table 2).

The number of confirmed cases in infants under 3 months, who are at most risk of severe disease and too young to be fully vaccinated, peaked at 407 cases in the earlier 2012 outbreak (Figure 3) then fell after the introduction of maternal vaccination. Pertussis is a cyclical disease that peaks every 3 to 5 years, with the last cyclical increase occurring in 2016. In recent years, cases in infants under 3 months increased from 2 cases in 2022 to 48 cases in 2023 but remained lower than pre-pandemic cyclical peak years; there were 83 cases in infants under 3 months in 2019 (Table 2). Incidence continued to be highest in infants under 3 months in 2023 (Figure 2). There were 108 infants aged under 3 months with confirmed pertussis between January and March 2024 whilst there were 70 cases in the same period in 2012.

In the 12 years prior to the introduction of maternal pertussis vaccination in October 2012, 63 deaths occurred in babies aged under one year with confirmed pertussis. Since the introduction of pertussis vaccination in pregnancy, from 2013 to the end of March 2024, there have been 26 deaths in babies with confirmed pertussis who were all too young to be fully protected by infant vaccination. Sadly, this includes 5 deaths in infants who had contracted pertussis in the first quarter of 2024. Of the 26 infants that died, 21 had mothers who were not vaccinated in pregnancy. Calculated vaccine effectiveness against infant death in those who received vaccine at least 7 days before delivery was 92% (UKHSA unpublished data).

Maternal vaccination is very effective against pertussis disease and hospitalisation (Optimization of Timing of Maternal Pertussis Immunization, Clinical Infectious Diseases 2023).

Vaccine uptake levels in pregnant women, babies and young children have fallen in recent years across England. Maternal vaccine uptake fell from 74.7% in December 2017 to 59.5% in December 2023, although this is an increase from around 58% uptake in September 2023. Vaccination in pregnancy is key to passively protecting babies before they can be directly protected by the infant vaccine programme. Pertussis vaccination is recommended in every pregnancy between 20 and 32 weeks, ideally after the 20-week scan, but can be given as early as 16 weeks for pragmatic reasons to ensure vaccination. It is also important that babies are vaccinated on time when they become eligible for infant doses at 8, 12 and 16 weeks of age and that those who miss vaccination are caught up at the earliest opportunity.

Guidelines for the public health management of pertussis provide details on the appropriate laboratory investigation of suspected cases of pertussis. This public health advice is informed by the age of the suspected case and time since onset of their symptoms. Appropriate confirmatory testing allows the situation to be closely monitored, ensures public health action is undertaken where needed and supports appropriate clinical management. Additional guidance on public health management during periods of increased pertussis activity has recently been published to be used alongside the main guidance.

Figure 1. Laboratory confirmed cases of pertussis by month in England: 2018 to March 2024 (note 1)

Figure 2. Annual incidence by age group of laboratory confirmed cases of pertussis in England: 2011 to 2023 (note 1)

Figure 3. Laboratory confirmed cases of pertussis by quarter in England: 2011 to 2024 (note 1)

Table 1. Laboratory confirmed cases of pertussis by reporting month in England: 2023, 2024 (note 1)

Month of reporting	Total number of cases reported, 2023	Cumulative total of cases for 2023	Total number of cases reported, 2024	Cumulative total of cases for 2024
January	9	9	556	556
February	9	18	918	1,474
March	12	30	1,319	2,793
April	20	50
May	33	83
June	53	136
July	72	208
August	93	301
September	102	403
October	102	505
November	110	615
December	243	858

Table 2. Laboratory confirmed cases of pertussis by age group in England: 2018 to 2023 and to March 2024 (note 1 and 2)

Age group	2018	2019	2020	2021	2022	2023	2024, cumulative to end March
Under 3 months	49	83	30	1	2	48	108
3 to 5 months	26	32	15	1	3	23	49
6 to 11 months	17	21	5	0	0	25	39
1 to 4 years	87	147	49	3	11	53	124
5 to 9 years	139	222	52	2	3	79	254
10 to 14 years	288	467	150	3	3	177	799
15 years and over	2,342	2,706	693	39	47	453	1,420
Total	2,948	3,680	994	49	69	858	2,793

[note 1] Data for 2023 and 2024 are provisional.

[note 2] 2019 total excludes 2 cases where the age was not known.

1. Deaths reported to the UKHSA pertussis enhanced surveillance programme from Health Protection Teams, Office of National Statistics or Patient Demographic Service. ↩